Greeting from the President
Kazuto Onda, President
Sakura Finetek Japan Co., Ltd. has consistently embraced new challenges to advance cancer diagnosis, positioning itself as a ‘total pathology solution provider’ that supports both pathology diagnosis and pathological testing. Our mission extends beyond the development and provision of high-quality, reliable products; we are also dedicated to providing our customers with the expertise and application services that support day-to-day pathology specimen preparation techniques.
The origins of the Sakura Group can be traced back to the pharmaceutical traders of the Edo period. For over 400 years, we have been contributing to the advancement of healthcare. Our company, responsible for the Asia region including Japan, operates globally alongside Sakura Finetek USA Inc. (North and South America), Sakura Finetek Europe B.V. (Europe, the Middle East, and Africa), and Sakura Medical Science Technology (Taizhou) Co., Ltd. in China. We continuously strive to meet all customer needs by staying abreast of the latest global trends. In addition, we lead the pathology market in terms of overall strength, in cooperation with our group companies in Japan, Sakura Seiki Co., Ltd., and Sakura Engineering Co., Ltd.
To support the future of pathology, which plays an increasingly important role in cancer diagnosis, we will continue to work closely with our customers involved in this field.